Results 41 to 50 of about 238 (77)

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer [PDF]

open access: yesCancer Immunology, Immunotherapy, 2012
Maio M   +12 more
openaire   +3 more sources

12P Multi-omics correlation with clinical outcome in metastatic melanoma patients treated with ipilimumab plus guadecitabine: The NIBIT-M4 study

open access: yesImmuno-Oncology and Technology, 2022
A.M. Di Giacomo   +9 more
openaire   +1 more source

Innovative tailored management of melanoma brain metastases

open access: yes
The occurrence of brain metastases (BM) in solid tumors is steadily increasing with the highest incidence being reported in melanoma (28.2%), lung (26.8%), renal (10.8%), and breast cancer (7.6%).
Elena Simonetti   +7 more
core  

A phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study

open access: yesAnnals of Oncology, 2015
L. CalabrĂ²   +9 more
openaire   +1 more source

MA 19.02 Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study

open access: yesJournal of Thoracic Oncology, 2017
L. Calabro   +11 more
openaire   +1 more source

Oleuropein potentiates the cytotoxic activity of dacarbazine against melanoma cells.

open access: yes, 2017
Calorini, Lido   +5 more
core  

Circulating Levels of PD-L1 in Mesothelioma Patients From the NIBIT-MESO-1 Study: Correlation With Survival [PDF]

open access: yesCancers, 2020
Targeting of the programmed cell death protein (PD)-1/programmed death-ligand 1 (PD-L1) axis has shown a significant clinical impact in several tumor types. Accordingly, our phase II NIBIT-MESO-1 study demonstrated an improved clinical efficacy in mesothelioma patients treated with the anti-PD-L1 durvalumab combined with the anti-cytotoxic T-lymphocyte
Sara Cannito   +2 more
exaly   +10 more sources

Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial

open access: yesClinical Cancer Research, 2019
Abstract Purpose: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies. The phase Ib NIBIT-M4 trial tested this hypothesis using the next-generation DHA guadecitabine combined with ipilimumab.
Andrea Anichini   +2 more
exaly   +14 more sources

Goals and Objectives of the Italian Network for Tumor Biotherapy (NIBIT)

open access: yesCytokine and Growth Factor Reviews, 2017
The explosion in the immuno-oncology field, exemplified by the clinical implementation of immune checkpoint inhibitor blockade and other immunotherapeutic strategies was quickly recognized by the Italian biomedical community, thanks to the networking activities of the Italian Network for Tumor Biotherapy (NIBIT), which has been active since 2004 in the
Pier Francesco Ferrucci   +2 more
exaly   +7 more sources

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases [PDF]

open access: yesClinical Cancer Research, 2021
Abstract Purpose: Phase II trials have shown encouraging activity with ipilimumab plus fotemustine and ipilimumab plus nivolumab in melanoma brain metastases. We report the primary analysis and 4-year follow-up of the NIBIT-M2 study, the first phase III trial comparing these regimens with ...
Paolo Marchetti   +2 more
exaly   +7 more sources

Home - About - Disclaimer - Privacy